The Biomedical Technology Program harnesses the expertise of scientists and engineers in collaboration with clinicians to develop new technologies, instruments, methods and algorithms that can be used for cancer screening, detection, diagnosis, treatment or treatment monitoring. The program draws primarily on science and engineering expertise from four key components, the Departments of Biomedical Engineering and Radiology at UC Davis, the NSF Center for Biophotonics Science and Technology (CBST), and the Lawrence Livermore National Laboratory (LLNL). In addition, clinical members of the program, from both the Medical School and School of Veterinary Medicine, with an expertise in radiology, radiafion oncology and surgery, are critical in guiding and supporting translational activities. Core themes of the program are technologies for cancer research and diagnosis, whole-body and organ imaging technologies, therapeutic technologies, biomarker discovery, and biosensors. These technologies span research, preclinical and clinical applications and include active collaborations with industry. They also cover spatial scales ranging from single molecules, through cells and tissues, to the whole-body level. The goals of the Biomedical Technology Program include: 1) create an environment that encourages development of technologies to address critical questions in cancer research and cancer care, 2) foster interactions between engineers, physicists and chemists with cancer biologists and physicians to guide the development process, 3) catalyze interactions to enable testing and validation of these technologies in pre-clinical models of cancer and in clinical settings;4) make technologies accessible through collaboration with cancer researchers and clinicians in other Cancer Center programs or via the shared resources as appropriate and 5) encourage interactions with industry that can lead to broader dissemination and adoption of these technologies. The program has 36 members from 10 different departments of UC Davis and 6 departments of LLNL. It has 18 NCl-funded projects for $3.2 million ADC (total peer-reviewed funding, $8.8 million ADC). The group has 869 publications for the last funding period;22% are inter-programmatic and 11% are intra-programmatic.

Public Health Relevance

This program brings together individuals from very different disciplines so that discoverise in the worlds of physics, mathematics, and engineering can through interactions with individuals in the medical and vet school be utilized to improve all aspects of the cancer continuum from prevention to cure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-12
Application #
8743644
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
12
Fiscal Year
2014
Total Cost
$22,221
Indirect Cost
$7,744
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Semrad, Thomas; Barzi, Afsaneh; Lenz, Heinz-Josef et al. (2015) Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol 20:518-24
Brostoff, Terza; Dela Cruz Jr, Florante N; Church, Molly E et al. (2014) The raccoon polyomavirus genome and tumor antigen transcription are stable and abundant in neuroglial tumors. J Virol 88:12816-24
Kirschbaum, Mark H; Foon, Kenneth A; Frankel, Paul et al. (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55:2301-4
Mayadev, Jyoti; Qi, Lihong; Lentz, Susan et al. (2014) Implant time and process efficiency for CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy 13:233-9
Daly, Megan E; Beckett, Laurel A; Chen, Allen M (2014) Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? Pract Radiat Oncol 4:240-6
Li, Tianhong; Maus, Martin K H; Desai, Sonal J et al. (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 9:18-25
Campbell, Mel; Kim, Kevin Y; Chang, Pei-Ching et al. (2014) A lytic viral long noncoding RNA modulates the function of a latent protein. J Virol 88:1843-8
Li, Tianhong; Kung, Hsing-Jien; Mack, Philip C et al. (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31:1039-49
Semrad, Thomas J; Eddings, Courtney; Dutia, Mrinal P et al. (2013) Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs 24:636-40
Maus, Martin K H; Mack, Philip C; Astrow, Stephanie H et al. (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8:582-6

Showing the most recent 10 out of 84 publications